Table 1.
Clinical background of patients at the time of pneumonectomy
| No. | Sex | Age (yr) | Pneumonectomy site | Diagnosis for pneumonectomy | Adjuvant treatment after pneumonectomy | Intervala) (mo) | FEV1 (L) | DLCO% | LVEF% |
|---|---|---|---|---|---|---|---|---|---|
| 1 | M | 77 | Lt (+pericardium) | Squamous cell carcinoma: pT3N1M0 (IIIA) | RTx | 77 | 1.17 | 50 | 60 |
| 2 | M | 59 | Lt | Squamous cell carcinoma: pT2bN0M0 (IIA) | CTx (taxol/carboplatin) | 33 | 1.58 | 62 | 69 |
| 3 | M | 61 | Lt | Squamous cell carcinoma: pT2aN1Mo (IIB) | CTx (cisplatin/vinorelbine) | 60 | 1.49 | 55 | 62 |
| 4 | F | 51 | Lt | Adenoid cystic carcinoma: pT2aN1M0 (IIB) | RTx (60 Gy/30 Fx) | 64 | 1.78 | 47 | 69 |
| 5 | M | 64 | Lt | Squamous cell carcinoma: cT4N2M0 (IIIB), ypT0N1 | - | 12 | 1.52 | 61 | 66 |
| 6 | M | 46 | Lt (+pericardium, aortab)) | Squamous cell carcinoma: cT3N2M0 (IIIB), ypT1bN1 | RTx (30 Gy/15 Fx), CTx (paclitaxel/cisplatin) | 24 | 2.12 | 44 | 55 |
| 7 | M | 70 | Lt | Squamous cell carcinoma: pT2aN0M0 (IB) | CTx (docetaxel/cisplatin) | 30 | 1.98 | - | 59 |
| 8 | M | 39 | Rt (+PA, PVR) | Angiosarcoma | - | 6 | 2.07 | - | 61 |
| 9 | F | 35 | Lt (+diaphragm) | Metastasis from osteosarcoma | - | 44 | 1.68 | 55 | 58 |
| 10 | F | 57 | Lt | Tuberculosis | - | 531 | 1.59 | 81 | 55 |
| 11 | M | 64 | Rt | Tuberculosis | - | 564 | 1.66 | - | 63 |
| 12 | F | 37 | Lt | Tuberculosis | - | 243 | 1.55 | 88 | 62 |
| 13 | M | 36 | Rt | Tuberculosis | - | 42 | 1.64 | 48 | 50 |
FEV1, forced expiratory volume in 1 second; DLCO, diffusion capacity for carbon monoxide; LVEF, left ventricular ejection fraction; Lt, left; RTx, radiotherapy; CTx, chemotherapy; Rt, right; PA, pulmonary artery; PVR, pulmonary valve replacement.
a)Time interval between pneumonectomy and contralateral lung resection surgery. b)Patient No. 6 received en bloc resection of the adventitia of the descending aorta.